Matritech NMP22 Assay Approvable As Adjunct Bladder Cancer Diagnostic
This article was originally published in The Gray Sheet
Executive Summary
Labeling for Matritech's NMP22 urine assay should state that the product is for use "in conjunction with and not in lieu of" standard bladder cancer detection procedures, FDA's Immunology Devices Panel concluded Dec. 13.